Merck MRK will report its second-quarter 2025 earnings on July 29, before market open. The Zacks Consensus Estimate for ...

“It shouldn’t be driving the narrative this much, but it’s become a credibility issue,” BMO analyst Evan Seigerman said. Starting in 2022, Gardasil fueled double-digit growth for Merck.

China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 yuan ($70) per dose, the state-owned Xinhua News Agency reports. | China’s ...

Merck issued guidance for 2025 that lags consensus amid struggles in China with Gardasil . Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ‘Buy’ rating on the stock and a $105 price target. According to analyst ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., primarily due to lower ...

Gardasil vaccine protects against cancer-causing human papilloma virus or HPV infections. The pause announcement comes a month after Merck received approval in China for use of the vaccine in males.

Gardasil and Gardasil 9 are together Merck's second best-selling product, with global sales of $8.58 billion in 2024. U.S. patent protection expires in 2028.